FERMENT LOVASTATIN ESTERASE, IMMOBILISED ON HARD CARRIER, METHOD OF FERMENT IMMOBILISATION, BIOCATALYSED FLOW REACTOR AND METHOD OF SIMVASTATIN TREATMENT Russian patent published in 2013 - IPC C12N11/08 C12N11/12 C12M1/40 C12P17/06 

FIELD: biotechnologies.

SUBSTANCE: ferment lovastatin esterase is proposed, which is immobilised on a water-insoluble hard carrier activated with a bifunctional agent. At the same time the hard carrier represents a modified di-(C_1-6alkyl)amino-C_1-6alkylcellulose, in another version the hard carrier represents a silica gel modified with amino-C_1-6alkyl-tri(C_1-6alkoxy)silane, and the bifunctional agent that activates the hard carrier represents O-sulfonate of cyanuric acid or acid halide of cyanuric acid. In the third version the hard carrier represents agarose, and the bifunctional agent is a compound that corresponds to the formula , as defined in the formula. Methods (versions) are proposed to immobilise the ferment lovastatin esterase on specified water-insoluble hard carriers. According to the methods, in process of mechanical mixing the bifunctional activating agent is brought in contact with the hard carrier in the dissolvent. The activated hard carrier is separated by filtration, then dried and suspended in a water mixture, containing the ferment lovastatin esterase, with performance of ferment immobilisation. The suspended substance is separated by filtration, washed with the buffer solution and dried. Also the method is proposed to treat simvastatin, including treatment of the simvastatin salt solution, containing the remaining amount of the lovastatin salt, immobilised witht the ferment lovastatin esterase, and a biocatalysed flow reactor is proposed with a layer for realisation of this method. The reactor comprises a reactor body (1) with the inner space (2), connected with a liquid inlet (3) and connected with a liquid outlet (4), in the inner space there is a perforated plate supporting the layer (5), containing the ferment lovastatin esterase, immobilised on the water-insoluble hard carrier.

EFFECT: immobilised lovastatin esterase according to the invention demonstrates at least 5 times higher hydrolytic activity in respect to lovastatin and lovastatin salts in presence of simvastatin and simvastatin salts than in respect to simvastatin and simvastatin salts.

18 cl, 2 dwg, 8 tbl, 20 ex